Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.

Hollestelle A, Peeters JK, Smid M, Timmermans M, Verhoog LC, Westenend PJ, Heine AA, Chan A, Sieuwerts AM, Wiemer EA, Klijn JG, van der Spek PJ, Foekens JA, Schutte M, den Bakker MA, Martens JW.

Breast Cancer Res Treat. 2013 Feb;138(1):47-57. doi: 10.1007/s10549-013-2415-3. Epub 2013 Jan 22.

PMID:
23338761
2.

Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.

Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1458-68. doi: 10.1158/1055-9965.EPI-11-1196. Epub 2012 Jun 28.

3.

Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.

Riaz M, Berns EM, Sieuwerts AM, Ruigrok-Ritstier K, de Weerd V, Groenewoud A, Uitterlinden AG, Look MP, Klijn JG, Sleijfer S, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2012 Jun;133(3):843-51. doi: 10.1007/s10549-011-1663-3. Epub 2011 Jul 12.

PMID:
21748294
4.

Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.

Nagel JH, Peeters JK, Smid M, Sieuwerts AM, Wasielewski M, de Weerd V, Trapman-Jansen AM, van den Ouweland A, Brüggenwirth H, van I Jcken WF, Klijn JG, van der Spek PJ, Foekens JA, Martens JW, Schutte M, Meijers-Heijboer H.

Breast Cancer Res Treat. 2012 Apr;132(2):439-48. doi: 10.1007/s10549-011-1588-x. Epub 2011 May 26.

PMID:
21614566
5.

Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.

Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M, Creemers GJ, Portielje JE, Pruijt JF, Loosveld OJ, Smit WM, Muller EW, Schmitz PI, Seynaeve C, Klijn JG; Dutch Breast Cancer Trialists' Group (BOOG).

Clin Breast Cancer. 2011 Apr;11(2):103-13. doi: 10.1016/j.clbc.2011.03.003. Epub 2011 Apr 11.

PMID:
21569996
6.

BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.

Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG.

J Clin Oncol. 2010 Dec 20;28(36):5265-73. doi: 10.1200/JCO.2009.27.2294. Epub 2010 Nov 15.

PMID:
21079137
7.

Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer.

Wasielewski M, Out AA, Vermeulen J, Nielsen M, van den Ouweland A, Tops CM, Wijnen JT, Vasen HF, Weiss MM, Klijn JG, Devilee P, Hes FJ, Schutte M.

Breast Cancer Res Treat. 2010 Dec;124(3):635-41. doi: 10.1007/s10549-010-0801-7. Epub 2010 Feb 27.

PMID:
20191381
8.

Early diagnosis of hereditary breast cancer by magnetic resonance imaging: what is realistic?

Klijn JG.

J Clin Oncol. 2010 Mar 20;28(9):1441-5. doi: 10.1200/JCO.2009.26.3467. Epub 2010 Feb 22. No abstract available.

PMID:
20177020
9.

Association of rare MSH6 variants with familial breast cancer.

Wasielewski M, Riaz M, Vermeulen J, van den Ouweland A, Labrijn-Marks I, Olmer R, van der Spaa L, Klijn JG, Meijers-Heijboer H, Dooijes D, Schutte M.

Breast Cancer Res Treat. 2010 Sep;123(2):315-20. doi: 10.1007/s10549-009-0634-4. Epub 2009 Nov 19.

PMID:
19924528
10.

Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition.

Obdeijn IM, Loo CE, Rijnsburger AJ, Wasser MN, Bergers E, Kok T, Klijn JG, Boetes C.

Breast Cancer Res Treat. 2010 Jan;119(2):399-407. doi: 10.1007/s10549-009-0607-7.

PMID:
19876732
11.

Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations.

Hollestelle A, Elstrodt F, Timmermans M, Sieuwerts AM, Klijn JG, Foekens JA, den Bakker MA, Schutte M.

Breast Cancer Res Treat. 2010 Jul;122(1):125-33. doi: 10.1007/s10549-009-0545-4. Epub 2009 Sep 18.

PMID:
19763817
12.

Low-risk susceptibility alleles in 40 human breast cancer cell lines.

Riaz M, Elstrodt F, Hollestelle A, Dehghan A, Klijn JG, Schutte M.

BMC Cancer. 2009 Jul 16;9:236. doi: 10.1186/1471-2407-9-236.

13.

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M.

Breast Cancer Res Treat. 2010 May;121(1):53-64. doi: 10.1007/s10549-009-0460-8. Epub 2009 Jul 11.

PMID:
19593635
14.

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.

Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, Blom J, Huijskens E, Jager A, van den Ouweland A, van Geel B, Hooning MJ, Brekelmans CT, Klijn JG.

J Clin Oncol. 2009 Aug 10;27(23):3764-71. doi: 10.1200/JCO.2008.19.9067. Epub 2009 Jun 29.

PMID:
19564533
15.

Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy.

Tan MB, Bleiker EM, Menke-Pluymers MB, Van Gool AR, van Dooren S, Van Geel BN, Tilanus-Linthorst MM, Bartels KC, Klijn JG, Brekelmans CT, Seynaeve C.

Hered Cancer Clin Pract. 2009 Mar 31;7(1):6. doi: 10.1186/1897-4287-7-6.

16.

Copy number alterations that predict metastatic capability of human breast cancer.

Zhang Y, Martens JW, Yu JX, Jiang J, Sieuwerts AM, Smid M, Klijn JG, Wang Y, Foekens JA.

Cancer Res. 2009 May 1;69(9):3795-801. doi: 10.1158/0008-5472.CAN-08-4596. Epub 2009 Mar 31.

17.

Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer.

Hooning MJ, Aleman BM, Hauptmann M, Baaijens MH, Klijn JG, Noyon R, Stovall M, van Leeuwen FE.

J Clin Oncol. 2008 Dec 1;26(34):5561-8. doi: 10.1200/JCO.2007.16.0192. Epub 2008 Oct 14.

PMID:
18854572
18.

Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.

Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM.

Clin Cancer Res. 2008 Sep 1;14(17):5555-64. doi: 10.1158/1078-0432.CCR-08-0555.

19.

CHEK2 1100delC and male breast cancer in the Netherlands.

Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M.

Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7. Epub 2008 Aug 31.

PMID:
18759107
20.

Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.

Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Wiemer EA, Martens JW.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13021-6. doi: 10.1073/pnas.0803304105. Epub 2008 Aug 28.

21.

CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.

Wasielewski M, Vasen H, Wijnen J, Hooning M, Dooijes D, Tops C, Klijn JG, Meijers-Heijboer H, Schutte M.

Clin Cancer Res. 2008 Aug 1;14(15):4989-94. doi: 10.1158/1078-0432.CCR-08-0389.

22.

A family history of breast cancer will not predict female early onset breast cancer in a population-based setting.

de Bock GH, Jacobi CE, Seynaeve C, Krol-Warmerdam EM, Blom J, van Asperen CJ, Cornelisse CJ, Klijn JG, Devilee P, Tollenaar RA, Brekelmans CT, van Houwelingen JC.

BMC Cancer. 2008 Jul 23;8:203. doi: 10.1186/1471-2407-8-203.

23.

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Helleman J, Sleijfer S, Klijn JG, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2009 Jul;116(2):263-71. doi: 10.1007/s10549-008-0125-z. Epub 2008 Jul 16.

PMID:
18629630
24.

The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine.

Foekens JA, Wang Y, Martens JW, Berns EM, Klijn JG.

Drug Discov Today. 2008 Jun;13(11-12):481-7. doi: 10.1016/j.drudis.2008.03.003. Review.

PMID:
18549973
25.

Subtypes of breast cancer show preferential site of relapse.

Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW.

Cancer Res. 2008 May 1;68(9):3108-14. doi: 10.1158/0008-5472.CAN-07-5644.

26.

Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.

Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, González-Neira A, Benítez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dörk T, Schürmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomäki K, von Smitten K, Blomqvist C, Mannermaa A, Uusitupa M, Eskelinen M, Tengström M, Kosma VM, Kataja V, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X; Australian Ovarian Cancer Management Group; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Devilee P, van Asperen CJ, Jacobi CE, Tollenaar RA, Huijts PE, Klijn JG, Chang-Claude J, Kropp S, Slanger T, Flesch-Janys D, Mutschelknauss E, Salazar R, Wang-Gohrke S, Couch F, Goode EL, Olson JE, Vachon C, Fredericksen ZS, Giles GG, Baglietto L, Severi G, Hopper JL, English DR, Southey MC, Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, Stram DO, Hunter DJ, Hankinson SE, Cox DG, Tamimi R, Kraft P, Sherman ME, Chanock SJ, Lissowska J, Brinton LA, Peplonska B, Klijn JG, Hooning MJ, Meijers-Heijboer H, Collee JM, van den Ouweland A, Uitterlinden AG, Liu J, Lin LY, Yuqing L, Humphreys K, Czene K, Cox A, Balasubramanian SP, Cross SS, Reed MW, Blows F, Driver K, Dunning A, Tyrer J, Ponder BA, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gabrieau V, Sigurdson A, Doody M, Struewing JP, Alexander B, Easton DF, Pharoah PD.

PLoS Genet. 2008 Apr 25;4(4):e1000054. doi: 10.1371/journal.pgen.1000054.

27.

Molecular profiles of progesterone receptor loss in human breast tumors.

Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R.

Breast Cancer Res Treat. 2009 Mar;114(2):287-99. doi: 10.1007/s10549-008-0017-2. Epub 2008 Apr 19.

28.

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.

Breast Cancer Res Treat. 2009 Jan;113(2):275-83. doi: 10.1007/s10549-008-9939-y. Epub 2008 Mar 4.

PMID:
18311582
29.

Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.

Wasielewski M, Hanifi-Moghaddam P, Hollestelle A, Merajver SD, van den Ouweland A, Klijn JG, Ethier SP, Schutte M.

Breast Cancer Res Treat. 2009 Jan;113(2):285-91. doi: 10.1007/s10549-008-9942-3. Epub 2008 Feb 24.

PMID:
18297428
30.

BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.

Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, Pointon L, Hill K, Klijn JG, Warren RM, Gilbert FJ.

Clin Cancer Res. 2007 Dec 15;13(24):7357-62.

31.

Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.

Huijts PE, Vreeswijk MP, Kroeze-Jansema KH, Jacobi CE, Seynaeve C, Krol-Warmerdam EM, Wijers-Koster PM, Blom JC, Pooley KA, Klijn JG, Tollenaar RA, Devilee P, van Asperen CJ.

Breast Cancer Res. 2007;9(6):R78.

32.

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.

Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, Magdolen V, Portengen H, Look MP, Klijn JG, Lesche R, Schmitt M, Maier S, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2008 Oct;111(3):429-37. Epub 2007 Oct 28.

PMID:
17965955
33.

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.

Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, van den Ouweland A, van Geel B, Brekelmans CT, Klijn JG.

Breast Cancer Res Treat. 2008 Sep;111(2):303-11. Epub 2007 Oct 19.

PMID:
17952592
34.

Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer.

Yu JX, Sieuwerts AM, Zhang Y, Martens JW, Smid M, Klijn JG, Wang Y, Foekens JA.

BMC Cancer. 2007 Sep 25;7:182.

35.

GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients.

Piersma D, Themmen AP, Look MP, Klijn JG, Foekens JA, Uitterlinden AG, Pols HA, Berns EM.

Breast Cancer Res. 2007;9(4):R51.

36.

Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?

Bresser PJ, Van Gool AR, Seynaeve C, Duivenvoorden HJ, Niermeijer MF, van Geel AN, Menke M, Klijn JG, Tibben A.

Ann Oncol. 2007 Oct;18(10):1641-5. Epub 2007 Jul 28.

PMID:
17660493
37.

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ.

J Clin Oncol. 2007 Sep 1;25(25):3859-65. Epub 2007 Jul 23.

PMID:
17646669
38.

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.

Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C; TRANSBIG Consortium.

Clin Cancer Res. 2007 Jun 1;13(11):3207-14.

39.

Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.

Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Tan M, Meijers-Heijboer HE, Klijn JG, Seynaeve C.

Ann Surg Oncol. 2007 Dec;14(12):3335-44. Epub 2007 May 31.

40.

Genome-wide association study identifies novel breast cancer susceptibility loci.

Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R; SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schürmann P, Dörk T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, van den Ouweland A, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X; kConFab; AOCS Management Group, Mannermaa A, Kosma VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA.

Nature. 2007 Jun 28;447(7148):1087-93.

41.

Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer.

Sieuwerts AM, Usher PA, Meijer-van Gelder ME, Timmermans M, Martens JW, Brünner N, Klijn JG, Offenberg H, Foekens JA.

Clin Chem. 2007 Jul;53(7):1280-8. Epub 2007 May 3.

42.

Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.

Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van Leeuwen FE, Van 't Veer LJ.

Breast Cancer Res. 2007;9(2):R26.

43.

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C.

J Clin Oncol. 2007 Apr 1;25(10):1239-46. Erratum in: J Clin Oncol. 2007 Aug 20;25(24):3790.

PMID:
17401012
44.

Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.

Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE.

J Natl Cancer Inst. 2007 Mar 7;99(5):365-75.

PMID:
17341728
45.

The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective study.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A.

Psychooncology. 2007 Dec;16(12):1121-9.

PMID:
17328098
46.

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.

Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van Gelder ME, van Staveren IL, Klijn JG, Foekens JA, Berns EM.

J Clin Oncol. 2007 Feb 20;25(6):662-8.

PMID:
17308270
47.

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.

Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG.

Eur J Cancer. 2007 Mar;43(5):867-76. Epub 2007 Feb 20.

PMID:
17307353
48.

Passive coping and psychological distress in women adhering to regular breast cancer surveillance.

Pieterse K, van Dooren S, Seynaeve C, Bartels CC, Rijnsburger AJ, de Koning HJ, Klijn JG, van Elderen T, Tibben A, Duivenvoorden HJ.

Psychooncology. 2007 Sep;16(9):851-8.

PMID:
17219399
49.

Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, van Gool AR, Klijn JG, Tibben A.

Clin Genet. 2007 Jan;71(1):35-42.

PMID:
17204044
50.

The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy.

Bresser PJ, Seynaeve C, Van Gool AR, Niermeijer MF, Duivenvoorden HJ, van Dooren S, van Geel AN, Menke-Pluijmers MB, Klijn JG, Tibben A.

Eur J Cancer. 2007 Jan;43(1):95-103. Epub 2006 Nov 13.

PMID:
17095208

Supplemental Content

Loading ...
Support Center